Coronavirus (COVID-19) opioid substitution treatment in prisons - evaluation: patient experience follow-up report

Footnotes

1. https://www.gov.scot/publications/coronavirus-covid-19-opiate-substitution-treatment-in-prisons---chief-medical-officer-letter/

2. May, C., Sharma, N., & Stewart, D. (2008). Factors linked to reoffending: a one-year follow-up of prisoners who took part in the Resettlement Surveys 2001, 2003 and 2004. London: Ministry of Justice.

3. Fazel et al. (2017). Substance use disorders in prisoners: an updated systematic review and meta‐regression analysis in recently incarcerated men and women. Addiction; 112: 1725–1739.

4. Sarah, et al. (2014). Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. BMJ open 4.4.

5. Figures available at: Prisoner health - ScotPHO

6. Nasser AF, Greenwald MK, Vince B, et al. (2016). Sustained-Release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder. J Clin Psychopharmacol; 36:18–26; Haight BR, Learned SM, Laffont CM, et al. (2019). Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet; 393:778–90; Lofwall MR, Walsh SL, Nunes EV, et al. (2018). Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical TrialEfficacy of subcutaneous Weekly and monthly vs daily sublingual dosing of buprenorphine for opioid use disorder. JAMA Internal Medicine; 178:764–73.

7. Gilman M., et al. (2018). Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine. Patient Prefer Adherence; 12:2123-2129; Neale J., et al. (2018). Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin. Drug Alcohol Dependence.;189:1–7; Tompkins C.N.E., Neale J., Strang J. (2019). Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder. Journal of Substance Abuse Treatment; 104:64–71.

8. https://www.gov.scot/publications/coronavirus-covid-19-opiate-substitution-treatment-in-prisons---chief-medical-officer-letter/

9. Available at: https://www.gov.scot/publications/coronavirus-covid-19-clinical-guidance-on-the-use-of-buvidal-in-prisons/

10. Available at: https://www.nice.org.uk/advice/es19/resources/opioid-dependence-buprenorphine-prolongedrelease-injection-buvidal-pdf-1158123740101

11. Chappuy et al. (2020). Readiness to try extended-released buprenorphine and related factors of interest: comparison between incarcerated and non-incarcerated subjects with opioid use disorder. Under Review by Harm Reduction Journal. Available at: https://www.researchsquare.com/article/rs-43617/v1 .

12. Sindicich, N., et al. (2016). Patient Motivations, Perceptions and Experiences of Opioid Substitution Therapy in Prison. National Drug and Alcohol Research Centre. University of New South Wales. Available at: https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/Technical%20Report%20Number%20332.pdf

13. Gillen, P. (2021) Drug Deaths in Scotland: an increasingly medical problem. Edinburgh: Royal College of Physicians of Edinburgh External Relations and Policy Department.

14. Available at: http://www.hra-decisiontools.org.uk/ethics/

15. Best, D., Irving, J., & Albertson, K. (2017). Recovery and desistance: what the emerging recovery movement in the alcohol and drug area can learn from models of desistance from offending. Addiction Research & Theory, 25(1), 1-10.

16. Graham L., et al, (2015). Understanding extreme mortality among prisoners: a national cohort study in Scotland using data linkage. European Journal of Public Health; 25(5), 879–885.

17. https://www.gov.scot/publications/drug-deaths-taskforce-covid-19-recommendations--16-april-2020/

18. Data from presentation given by Buvidal West Lothian Community Addictions Service presented at Drugs Research Network Scotland 'Knowledge Exchange Event: Long-Acting Injectable Buprenorphine', 27^th January, 2021.

19. Pilot report Greater Glasgow & Clyde: NHS GGC Alcohol Drug Recovery Services. Presentation at Drugs Research Network Scotland seminar: presented at Drugs Research Network Scotland 'Knowledge Exchange Event: Long-Acting Injectable Buprenorphine', 27^th January 2021.

20. Loucks, N. (2010) "Women in prison." In Forensic Psychology. Adler, R, J., & Gray, M, J. (eds). P. 142-158. Abingdon: Willan Publishing.

21. Light et a., (2013). Gender differences in substance misuse and mental health amongst prisoners. Results from the Surveying Prisoner Crime Reduction (SPCR) longitudinal cohort study of prisoners. London: Ministry of Justice.

22. The Scottish Government (2015) International Review of Custodial Models for Women: Key Messages for Scotland. Edinburgh: The Scottish Government.

23. The Scottish Government (2015) What Works to Reduce Reoffending: A Summary of the Evidence. Edinburgh: The Scottish Government.

24. McIvor, G., Trotter, C., Sheehan, R. (2009). Women, resettlement and desistance. Probation journal; 56(4): 347-361; Barry, M. (2007) 'The Transitional Pathways of Young Female Offenders: Towards a Non-Offending Lifestyle', in Sheehan, R., McIvor, G., Trotter, C. (eds) What Works with Women Offenders. Cullompton: Willan Publishing.

25. Wright, Nat, et al. (2020) OUD Care Service Improvement with Prolonged-release Buprenorphine in Prisons: Cost Estimation Analysis. Clinicoeconomics and Outcomes Research: CEOR 12: 499; Phillips-Jackson, Helen, et al. (2020). Budget impact analysis of the introduction of injectable prolonged-release buprenorphine on opioid use disorder care resource requirements. ClinicoEconomics and Outcomes Research; CEOR 12: 233.